Biotechnology companies are increasingly contributing and innovating new therapies in cancer science. Biotech companies that are focused on the need for cancer drugs are going to benefit. The cancer market is projected to reach $161.30 billion by 2021, according to Zion Market Research the Global. There are a few companies that are suggested to start following: Biopharma, Inc, Kura Oncology, Inc, NewLink Genetics Corporation, Stemline Therapeutics, Inc, and Verastem, Inc.
Propanc Biopharma, Inc.
PPCB’s FDA Orphan Drug Designated pancreatic cancer therapy, PRP, is an intravenous combination of two pancreatic proenzymes. PRP targets tumors to prevent the recurrence and metastasis, the main cause of death from cancer.
CEO, James Nathanielsz, stated in a press release, “We are very pleased with the progress of the purification and characterization of the two key active components for PRP, trypsinogen and chymotrypsinogen, and we’re now moving into the Good Manufacturing Practice (GMP) phase of the manufacturing process, to ensure the IMP meets the strict guidelines for pharmaceutical use in humans.”
The company is also preparing the documentation for a supporting clinical trial application and an Orphan Drug Designation (ODD) application to the FDA for the treatment of ovarian cancer.
Kura Oncology, Inc.
KURA saw its shares double after the company announced results from its mid-stage trial in patients with HRAS, mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC).
NewLink Genetics Corp.
NLNK focuses on the discovery, development, and commercialization of novel immuno-oncology products aiming to improve the quality of life of cancer patients. NLNK released data from an ongoing Phase 2 study of indoximod, NewLink Genetics’ IDO pathway inhibitor, also with the PD-1 pathway inhibitor, KEYTRUDA (pembrolizumab).
Stemline Therapeutics, Inc.
STML, a clinical-stage company developing novel therapeutics for difficult to treat cancers, released clinical data from a Phase 1 trial in patients with advanced solid tumors. The data was presented at the European Society of Medical Oncology (ESMO) Annual Congress.
Verastem, Inc. Market Cap:
VSTM a clinical stage company that focuses on discovering and developing medications to improve patient outcomes. Verastem, Inc.’s stock recently reached a new 52-week high after announcing the expansion of its duvelisib development program to include peripheral t-cell lymphoma after receiving fast track designation by the FDA.